# This Page Is Inserted by IFW Operations and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

## IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents will not correct images, please do not report the images to the Image Problem Mailbox.

CERTIFICATE OF MAILING

Thereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on the date appearing below.

ELI LILLY AND COMPANY

By 43 Bhoades

Date 8-19-98

PATENT APPLICATION

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

AUG 2 1 199

Applicants : Brader, et al.

Serial No. : 08/484,542

Filed : 7 June 1995

For : Stabilized Acylated Insulin

Formulations

Docket No. : X-10097

Group Art Unit:

1645

Examiner:
Allen, M.

#### DECLARATION UNDER 37 C.F.R. §1.131

Assistant Commissioner for Patents Washington, D. C. 20231

### BEST AVAILABLE COPY

Sir:

We, Mark L. Brader and Michael J. Beckage, declare that:

We are co-inventors and applicants in this application.

Attached exhibits 1, 2, and 3 are copies of pages from Michael J. Beckage's notebook in which he recorded the preparation of a formulation comprising an aqueous solution of a fatty acid-acylated insulin and approximately 0.35 mole of zinc per mole of said fatty acid-acylated insulin, and having a pH of approximately 7.5. The fatty-acid acylated insulin was  $N^{\epsilon}$ -Lys<sup>B29</sup>-palmitoyl-human insulin, which is referred to as C16-insulin. The formulation also contained m-cresol, a phenolic compound, at a concentration of approximately 2.5 mg/mL.

The dates have been redacted. All the actions, events, and observations described in exhibits 1, 2, and 3 occurred in the United States, prior to 17 November, 1994, the date of the filing of the patent application from which U.S. Patent No. 5,693,609 issued.

We further declare that all statements made herein of our own knowledge are true, that all statements made on

information and belief are believed to be true, and that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both (18 U.S.C. 1001), and may jeopardize the validity of the application or any patent issuing thereon.

4/29/98

Date

4/29/98

Date

Mark L. Brader

Mark L. Brader

Michael J. Beckage

**BEST AVAILABLE COPY** 



